Oramed Pharmaceuticals 2023 Investor Presentation: Oral Drug Delivery

Oramed Pharmaceuticals presents its proprietary oral protein delivery platform targeting the injectable drug market, with initial focus on insulin for diabetes. The company holds 88 granted patents and 35 pending applications, backed by $150.2M in cash with no debt and multiple value-creation catalysts planned for 2023.